reviewed april 2026|next review october 2026|88 physicians psi has verified|3 published studies
GDF-11 (Growth Differentiation Factor 11)
GDF-11 (growth differentiation factor 11) is the TGF-beta superfamily member at the center of the 'young blood' controversy, with conflicting published data on whether it reverses or exacerbates age-related tissue decline.
Evidence landscape: 3 published studies
3 published items under this slug. The broader GDF-11 literature includes over 500 studies.
- 3 Reviews
Not FDA-approved. Not in clinical development. No therapeutic application has been established. The scientific evidence itself is contested between independent research groups.
Not available as a therapeutic. Recombinant GDF-11 is available for research purposes only. Any commercial 'GDF-11' product should be viewed with extreme skepticism given the unresolved scientific debate.
GDF-11 is a naturally occurring (the body's own) TGF-beta superfamily member that shares 90% amino acid homology with myostatin (GDF-8). It signals through ActRII receptors. The parabiosis (shared circulation) experiments that identified GDF-11 as a rejuvenation candidate remain among the most debated findings in aging biology.
PSI Assessment
In 2013, Harvard researchers published findings that connected the blood supply of young and old mice and observed reversal of age-related cardiac hypertrophy in the old mice. GDF-11 was identified as a candidate circulating factor responsible for this rejuvenation effect. The findings generated enormous excitement and mainstream media coverage. Subsequent studies from independent laboratories produced directly conflicting results: some found GDF-11 levels increase rather than decrease with age, and some reported that recombinant GDF-11 caused muscle wasting rather than regeneration. The fundamental questions remain unresolved. Whether GDF-11 is a rejuvenation factor or a harmful molecule in aging represents one of the most prominent unresolved debates in aging biology.
The 'young blood' molecule. Conflicting published data on whether GDF-11 reverses or worsens aging. One of the most prominent unresolved debates in aging biology.
GDF-11 is a TGF-beta superfamily member that shares 90% amino acid sequence homology with myostatin (GDF-8) but has distinct biological roles. It signals through ActRII/ALK4/5 receptors, activating Smad2/3 transcription factors. The original parabiosis research identified GDF-11 as declining with age and contributing to stem cell dysfunction in heart, brain, and muscle. Counter-studies using different assays found GDF-11 may actually increase with age, and the high structural similarity to myostatin meant some assays could not reliably distinguish between the two proteins. GDF-11 plays confirmed roles in embryonic development (anterior-posterior patterning), neurogenesis, and hematopoiesis.
What the evidence supports
GDF-11 was identified in parabiosis experiments as a candidate rejuvenation factor. The original 2013 Cell paper showed reversal of age-related cardiac hypertrophy (Wagers lab). GDF-11 shares 90% amino acid homology with myostatin but has distinct biological roles. The TGF-beta superfamily signaling pathway through ActRII receptors is established.
What is not yet established
Whether GDF-11 levels decline or increase with age (conflicting published data). Whether GDF-11 is rejuvenating or harmful (directly conflicting reports from independent laboratories). Whether the parabiosis rejuvenation effects are attributable to GDF-11 specifically or to other factors in young blood. Any aspect of therapeutic application.
Research Evidence
The findings below cover both the original rejuvenation hypothesis and the subsequent contradictory data that has complicated the field.
Evidence by condition
Evidence dimensions available for each condition GDF-11 (Growth Differentiation Factor 11) has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Aging / Rejuvenation Research | ||||
| Cardiac Hypertrophy | ||||
| Neurogenesis | ||||
| Muscle Biology |
The original 2013 Cell paper (Loffredo et al., Wagers lab at Harvard) demonstrated that parabiosis reversed age-related cardiac hypertrophy in old mice, and identified GDF-11 as a candidate circulating factor. Recombinant GDF-11 administration replicated the cardiac effect.
This was the foundational study for the 'young blood' rejuvenation hypothesis. Subsequent studies from other laboratories produced conflicting results, creating one of the most prominent scientific controversies in aging biology.
0 Human|0 Animal|3 Reviews
View all 3 indexed studiesHow GDF-11 (Growth Differentiation Factor 11) Works
GDF-11 is a naturally occurring (the body's own) TGF-beta superfamily member that signals through ActRII/ALK4/5 receptors and Smad2/3. It shares 90% amino acid homology with myostatin (GDF-8). It plays confirmed roles in embryonic development, neurogenesis, and hematopoiesis.
GDF-11 is a protein found in blood that may carry signals from young tissue to old tissue. The original research showed that connecting the blood supply of young and old mice reversed aging features in the old mice. GDF-11 was identified as a candidate molecule responsible for this effect.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
GDF-11 is a TGF-beta superfamily member that signals through ActRII/ALK4/5 receptors and Smad2/3. It regulates anterior-posterior patterning during development. The rejuvenation hypothesis proposes that declining GDF-11 with age contributes to stem cell dysfunction in heart, brain, and muscle. Counter-studies found GDF-11 may actually increase with age using different assays.
What is GDF-11 (Growth Differentiation Factor 11) being studied for?
Researchers are studying GDF-11 (Growth Differentiation Factor 11) across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for GDF-11 (Growth Differentiation Factor 11) overall. This means a compound can have human studies for one condition but only animal data for another.
Aging / Rejuvenation Research
·Animal StudiesThe parabiosis experiments demonstrated that young blood factors reverse aging features in old mice. Whether GDF-11 specifically is the responsible factor is contested. The original cardiac rejuvenation data is reproducible by the originating laboratory but disputed by others.
Limitations: Directly conflicting published data from independent laboratories. No human data. Assay specificity issues (GDF-11 vs myostatin cross-reactivity) have complicated measurement.
Cardiac Hypertrophy
·Animal StudiesThe original 2013 study showed GDF-11 reversed age-related cardiac hypertrophy in mice. This was the finding that launched the 'young blood' hypothesis.
Limitations: Replication by independent laboratories has been inconsistent. Whether GDF-11 specifically (versus other parabiosis factors) drives the cardiac effect is debated.
Neurogenesis
·PreclinicalParabiosis increased neurogenesis and vascular remodeling in aged mouse brains. GDF-11 was one candidate mediator.
Limitations: The neurogenesis effects may be attributable to other factors in young blood. GDF-11-specific neurogenesis data is limited.
Muscle Biology
·PreclinicalInitial studies suggested GDF-11 restores muscle satellite cell function. Subsequent studies reported the opposite: GDF-11 caused muscle wasting similar to its structural relative myostatin.
Limitations: Directly contradictory published findings. The 90% homology with myostatin raises the possibility that GDF-11 inhibits rather than promotes muscle growth.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not in clinical development. No therapeutic application has been established. The scientific evidence is contested.
Availability: Not available as a therapeutic. Recombinant GDF-11 is available for research only. Commercial products are unverified.
Class context: GDF-11 is a naturally occurring (the body's own) protein. No human therapeutic studies have been conducted. The unresolved question of whether GDF-11 is beneficial or harmful means any commercial product should be viewed with skepticism.
GDF-11 is a naturally occurring (the body's own) protein. No human therapeutic studies have been conducted. The scientific controversy means any commercial GDF-11 product should be viewed with extreme skepticism. No FDA-approved GDF-11 therapeutic exists.
Questions and Comparisons
Questions the evidence raises for a GDF-11 (Growth Differentiation Factor 11) discussion.
Comparison and Related Research
GDF-11 sits within the aging biology and TGF-beta superfamily research space. The comparisons clarify its contested position.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Landmark study from the Wagers laboratory demonstrating that GDF-11, a circulating factor found at higher levels in young blood, could reverse age-related cardiac hypertrophy in old mice when administered via parabiosis or recombinant protein injection. This paper generated enormous interest in GDF-11 as a potential anti-aging factor.Loffredo FS et al., 2013 in Cell. View on PubMed
- 2.Published conflicting data challenging the original anti-aging narrative. This study reported that GDF-11 levels actually increase with age (contradicting Loffredo 2013) and that GDF-11 inhibits rather than promotes muscle regeneration. The contradiction sparked a significant scientific debate about the role of GDF-11 in aging that remains unresolved.Egerman MA et al., 2015 in Cell Metab. View on PubMed
- 3.Companion study to the Loffredo 2013 paper, extending the findings to skeletal muscle. Reported that supplementing GDF-11 in old mice improved muscle satellite cell function, increased exercise capacity, and reversed age-related structural changes in muscle. Together with the cardiac study, this positioned GDF-11 as a broad rejuvenation factor.Sinha M et al., 2014 in Science. View on PubMed
- 4.Comprehensive review examining the biological relationship between GDF-11 and myostatin, two closely related TGF-beta superfamily members that share 90% amino acid sequence similarity. Addressed the measurement challenges that contributed to conflicting results and outlined key questions that needed resolution in the field.Walker RG et al., 2016 in Circ Res. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.